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13. Nguyen G, Delarue F, Berrou J, Rondeau E, Sraer JD. Specific expression of plasminogen activator inhibitor-1 in cultured endothelial cells. J Clin Invest 1995; 95: 995-1001 receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen. Kidney Int 23. Pueyo ME, Arnal JF, Rami J, Michel JB. Angiotensin II stimulates the production of NO and peroxynitrite in endothelial 1996; 50: 1897 -1903 In the past, based on inconsistent data, many authors reinforced the conclusion that available evidence was inconsistent and limited; therefore the case remains insisted that calcium-channel blockers (CCB) presented open whether CCB have adverse or beneficial effects a risk when used for the therapy of patients with on the risks of coronary heart disease, cancer, and arterial hypertension. In July 1996, the liaison combleeding. mittee of the World Health Organisation and the In the meantime data in favour of a positive effect International Society of Hypertension combined and of CCB were published in the Systolic Hypertension formed an ad-hoc subcommittee to assess the available in Europe (SYST-EUR) trial [3] . In this study a longpublished and unpublished evidence on the effects of acting member of the dihydropyridine subclass of CCB CCB on the risks of coronary heart disease, cancer was shown to reduce the rate of cardiovascular comand bleeding. After extensive review the subcommittee plications among elderly patients with isolated systolic issued a report describing which methodological prinhypertension. According to these data, the sixth report ciples had been adopted for the assessment, summarizof the Joint National Committee [4] considered that ing the main evidence and stating its findings [1] . The isolated systolic hypertension was a compelling indicasubcommittee concluded that the available evidence tion for the therapy with long-acting dihydropyridines. concerning the effects of CCB on coronary heart
In 1998 the controversy reappeared with the disease, cancer, and bleeding did not establish any publication of the results of the ABCD trial in the effect, beneficial or harmful, of CCB on those items. New England Journal of Medicine [5] . The appropriate A more recent publication by MacMahon et al. [12] , that because of their documented effects ACE inhibitors should be plications of diabetes. The study also compared nisoldipine with enalapril as first-line antihypertensive agents. preferred as first line agents in patients with renal failure and hypertension. However, the contribution Analysis of the 470 patients in the trial who had hypertension showed a similar control of blood pres-of CCBs to obtain the adequate control of blood pressure and proteinuria, used alone or in association sure, blood glucose and lipid concentrations with both antihypertensive drugs. Whereas, a significantly higher with other antihypertensive agents remains to be elucidated [13] . An ongoing study, the Collaborative Study incidence of fatal and non-fatal myocardial infarction was found among those assigned to therapy with the [14], will greatly contribute to answer this question.
In this study a group of almost 1600 type 2 diabetic CCB nisoldipine compared to those assigned to enalapril. The authors concluded that since the findings were patients are being followed and treated in a doubleblind fashion with irbesartan, amlodipine, or placebo. based on a secondary endpoint, they required confirmation. This study prompted an editorial in The The goal of blood pressure control in this study is <130/85 mmHg, and the placebo arm will allow us to Lancet [6 ] ; its authors concluded that until large randomized trials are completed, ACE inhibitors and know the effectiveness of an adequate control of blood pressure per se. low dose diuretics remain the preferred first-line agents for hypertensive patients with diabetes.
A few weeks ago the final results of the hypertension References optimal treatment (HOT ) trial have been published [7] . This trial included a total of 18 790 patients, aged for patients with diabetes as well as other groups of 13: 1930-1932 patients, will have to await the results of the current 12. Schrier RW, Estacio RO. Comment to the editorial of generation of randomized trials [9] . P. Zucchelli. Nephrol Dial Transplant 1998; 13: 1932 -1933 13. Ruilope LM, Campo C, Rodicio JL. Blood pressure control, On the other hand, the capacity of CCBs to retard proteinuria and renal outcome in chronic renal failure. Curr the progression of chronic renal failure remains to be Opin Nephrol Hypertens 1998; 7: 145-148 elucidated [10] . The controversy on cardiovascular 14. Ruilope LM. Renoprotection and renin-angiotensin system safety of CCBs has contributed to deny these drugs as blockade in diabetes mellitus. Am J Hypertens 1997; 12(2): 325S-331S first-step therapy in patients with chronic renal failure,
